Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 6, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements on January 29, 2007, involving the SmithKline Beecham Employee Benefit Trust:
- Sales: 377 Ordinary shares were sold on behalf of a participant in the SmithKline Beecham Annual Investment Plan at a price of GBP 13.90 per share.
- Transfers: 1,239 Ordinary shares were transferred from the Trust to a participant in the same plan.
Management Commentary and Risks
The filing notes that the Trust is a discretionary fund for non-US employees and former employees. Director Mr. J S Heslop is identified as having an interest in the shares held in the fund in the same capacity as other eligible employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b). No broader outlook, risks, or unusual items are discussed in this specific filing.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the reported transactions.
- Confirm the current share price relative to the GBP 13.90 transaction price mentioned in the filing.
- Review the full list of directors and their specific interests in the Trust to understand potential conflicts or alignment with employee incentives.